1. Introduction {#sec1}
===============

Clear cell sarcoma (CCS) is a rare malignant tumor that was described first by Enzinger in 1965 \[[@B1]\]. CCS shows a predilection for the deep soft tissues of the lower extremities close to the tendon, fascia, or aponeuroses \[[@B2]\]. It occurs preferentially in adolescents and young adults and is associated with a high propensity of local recurrence, regional lymph node metastases, and distant metastases \[[@B1], [@B2]\]. Because of its close clinic and histologic kinship with malignant melanoma (high frequency of lymph node metastases, presence of melanin, ultrastructural evidence of melanosomes, and immunohistochemical staining for S-100 protein and melanoma-associated antigen HMB-45), Chung and Enzinger proposed the name malignant melanoma of soft parts \[[@B2]\]. However, despite these similarities, CCS and melanoma should be considered 2 distinct entities. Unlike melanomas, most CCS tumors are characterized by a recurrent chromosomal translocation, t(12; 22), resulting in fusion of the EWS gene on 22q12 with the ATF1 gene on 12q13 \[[@B3]\]. Several fusion transcript types have been described, with a predominance of type 1 fusing exon 8 of EWS with exon 4 of ATF1 and type 2 fusing exon 7 of EWS with exon 5 of ATF1 \[[@B4]\]. The prevalence of t(12; 22) fusion transcripts detected by molecular techniques has been reported in only 3 small series of 10 patients, 12 patients, and 9 patient with CCS \[[@B3]--[@B5]\].

High incidence of activating mutations in the BRAF gene has been reported in melanoma cell lines, melanoma short-term cultures, primary and metastatic melanomas, and nevi \[[@B6]\]. All the mutations were detected in the kinase domain of the BRAF gene and found in exons 11 and 15. The most common mutation (V599E) is the T1796A single-base substitution in exon 15, leading to an exchange of valine for glutamic acid at position 599 \[[@B6]\].

This mutation was not reported in soft tissue sarcomas including a small series of 8 CCS \[[@B4]\]. Compared with the extensive literature regarding the histopathologic nature of the disease, very little is known about the clinical and molecular features of CCS. The main obstacle to gaining a thorough understanding of the clinical and molecular behavior of CCS is the rarity of the disease.

We describe the clinicopathological data of 52 patients with clear cell sarcoma with emphasis on prognostic factors and treatment outcomes. Mutational status on BRAF, NRAS gene, and cytogenetic study of translocation (12, 22) (q13, q12) were also studied ([Table 1](#tab1){ref-type="table"}).

2. Patients and Methods {#sec2}
=======================

Between April 1979 and April 2005, 52 consecutive cases of CCS were registered at the Gustave Roussy, Villejuif (46 patients) and Bergonie, Bordeaux (6 patients) institutes.

Complete information on clinical data, treatment modalities, and outcome was reviewed in all cases to exclude an antecedent or a concurrent diagnosis of primary cutaneous melanoma. When the initial biopsies were done outside the institutes, the histopathologic diagnosis was confirmed by Gustave Roussy or Bergonie Institute expert of pathologists. Histologic criteria for the diagnosis of CCS are the intimate association of small solid aggregates of round-to-fusiform, pale-staining cells within the dense connective tissue of tendons and aponeuroses, the fine reticular stroma surrounding the cells, the relative uniformity of cells showing abundant clear cytoplasm, and scattered multinucleated giant cells. Mitotic figures are generally infrequent. A confirmation of diagnosis is obtained by immunohistochemistry with a diffuse or focal positivity for S-100 protein and melanocyte-associated antigen HMB-45, positivity for neuron-specific enolase (NSE). Thirty-one cases were examined for the presence of EWS/ATF1 transcripts by real-time PCR on paraffin-embedded tissues and frozen samples.

DNA was prepared from paraffin-embedded tissues of 22 CCS (16 cases from GRI, 6 cases from BI) carrying the t(12; 22) translocation. PCR amplification of BRAF exons 11 and 15 as well as NRAS codons 12, 13, and 61 was performed, and PCR products were sequenced.

The following demographic and treatment factors were examined for prognostic importance: patient age (≤30 years, \>30 years), sex, tumor size (≤4 cm, \>4 cm), location, symptoms, clinical staging, microscopic surgical margin, chemotherapy and radiotherapy, mitotic rate (\>2 per 10 high power fields after examining and averaging data from 20 HPF), and presence of necrosis.

With respect to tumor location, proximal sites included the trunk and proximal extremities (upper arm and thigh), and distal sites included distal extremities (below or at the elbow and below or at the knee joint). The microscopic surgical margin was determined histologically on the resected specimens and was classified as negative (no tumor cells at the inked margin) or positive (tumor cells at the inked margin). Patients received multimodality treatment, including surgery, radiotherapy, and chemotherapy. Wide excision of the primary tumor with a negative surgical margin was attempted whenever possible. If necessary, amputation/disarticulation was planned to achieve a negative surgical margin.

All time-to-event endpoints were computed by using the kaplan-Meier method \[[@B7]\].

Patients who died of causes unrelated to CCS were censored at time of death. Potential prognosis factors were identified by univariate analysis using the log-rank test. Independent prognostic factors were evaluated with Cox proportional-hazards regression using a stepwise selection procedure \[[@B8]\]. To arrive at a parsimonious multivariate model, covariates were selected into the model only if they contributed significantly to the fit of the model. The criterion used to select covariates into the model was the score chi-square statistic. Differences at *P* \< .05 were considered significant. Statistical analyses were performed using the StatView 5 statistical package.

3. Results {#sec3}
==========

The study group comprised 30 men (57.69%) and 22 women (42.30%), and patients ranged in age from 6 years to 81 years (median, 33 years). Forty-two percent of patients were aged ≤30 years, and 94% were aged \<60 years.

Forty-three tumors (82.69%) were located in the extremities, eight tumors (15.38%) were located in the trunk, and one tumor was located in the scalp. The most common tumor site was the foot (19 tumors), followed by the hand (13 tumors), and the thigh (9 tumors). Fourteen tumors (26.92%) were considered proximal, and 38 tumors (73.07%) were considered distal.

Fifty patients (96.15%) had a mass that had been enlarging slowly for periods ranging from six weeks to four years (median, 15 weeks). Pain and/or tenderness were observed in 30 patients (57.69%), and this was frequently the main reason for seeking medical advice. In two patients, acute urinary retention was the first sign of the disease. No patients had a history of melanoma or unusual pigmented skin lesions.

At presentation the malignant nature of the swelling was seldom suspected, and in thirty-six patients (69.23%), a biopsy was performed. Nevertheless in sixteen patients (30.76%), the lesion was thought to be benign on clinical grounds, and initial clinical diagnosis included epithelial cyst (7 patients) exostose (4 patients), haematoma (2 patients), and neurinoma, lipoma, and carpal tunnel syndrome (1 patient each).

Initial diagnosis was made at another institution in all cases, with incisional or excisional biopsy. All cases were reviewed by the Gustave Roussy or the Bergonie Institute soft tissue pathologists.

The tumors ranged in size from 1 cm to 15 cm (median, 4, 86 cm). The tumors measured \<4 cm in 30 patients (57.69%) and between 4 cm and 15 cm in 21 patients (40.38%). Tumor size was unknown in one patient.

In all cases, the tumor cells were arranged in nests, clefts, and an alveolar pattern, separated by fibrous septa. Some dyscohesive cells were seen lying in spaces. The cells showed necrosis less than 50% in 33 patients (63.46%), more than 50% in 14 patients (26.92%), and no evidence of necrosis in 5 patients (09.61%). Of the fourteen patients who had necrosis more than 50%, ten patients died. The number of mitoses was less than 10 per high power fields (10 HPF) in 27 patients (51.92%), between 10 and 20 per 10 HPF in 21 patients (40.38%), and more than 20 per HPF in 4 patients (7.69%). Forty tumors (76.92%) were grade 2, and twelve tumors (23.07%) were grade 3 using the FNCLCC grading system.

HMB45 was diffusely positive in forty-four tumors (84.61%) and focally positive in 8 patients (15.38%). S100 protein was largely positive in forty-four patients (84.61%), focally positive in 5 cases (09.61%), and negative in 3 cases (5.76%). Melan A and MITF were expressed in many cases (76.92% and 84.6% of cases, resp.) including S100 protein-negative tumors. Vimentin could be detected in 3 cases (5.76%). None of our cases had expressions of keratin. Only one of the 22 CCS harboured a BRAF mutation (V599E); it was the well-known valine to glutamic acid change in position 599. No exon 11 mutation were found. One mutation of NRAS (codon 61) was also found with no overlap with the BRAF mutation. The EWS/ATF-1 fusion transcript was detected in 28 patients of the 31 paraffin-embedded CCS, and 3 of the 31 patients were negative. The two tumours that presented a BRAF or NRAS mutation also presented the ATF1-EWS fusion gene and were considered atypical. However, the absence of cutaneous involvement, histologic features (spindle and a few epithelioid cells arranged in a nested pattern), and immunohistochemistry (diffuse positivity for S100 protein and HMB45) strongly suggested a diagnosis of CCS.

Forty-nine patients (94.23%) presented with localized disease; forty-four patients (84.61%) of them underwent surgical resection of primary tumor. Nineteen patients (36.53%) underwent complete surgical resection with negative margins; twenty-five patients (48.07%) had residual microscopic disease and underwent adjuvant therapy especially radiotherapy.

The last five patients with localized disease received neoadjuvant chemotherapy before surgical resection in order to reduce tumors size and make surgical resection possible.

Two patients (3.84%) presented with disease metastatic to lymph nodes. One patient presented with disease metastatic to both lymph nodes and lung.

Definitive surgical management included wide local excisions in 29 patients, local excision in 11 patients, radical compartment resection in 4 patients, and amputation in 3 patients. Adjuvant treatment was given to 42 patients and consisted of radiotherapy in 40 patients (76.92%) with a median of 50 grays. This radiotherapy was associated to adjuvant chemotherapy in 10 patients, and 2 patients received adjuvant chemotherapy alone.

29 patients (55, 76%) developed local recurrence. The time interval from initial treatment to local relapses ranged from 1 month to 20 years, with a median of 38 months. Local recurrence was seen in 55% of the 29 patients at 5 years and 63% at 10 years. Sixteen of these patients received additional surgical treatment and 3 had amputation. Of the other 10 patients (19.23%), they were already known to have regional lymph node metastases and/or had disseminated disease. Of the 29 patients (55, 76%) who had local recurrences, 19 (36.53%) died of the tumors, three (5.76%) are alive with disease, but only seven (13.46%) patients are alive free of disease.

No local recurrences occurred in 23 patients (44.23%) who had surgical resection with negative margins (16 patients) or with positive margins associated to adjuvant radiotherapy (7 patients). The overall survival rate without local recurrence was 30% at 5 years and 16% at 10 years.

Nineteen patients developed regional lymph node metastases at 5 years in 34% and at 10 years in 41% of them. Of these patients, six (11.53%) had lymph node metastases within less than 1 year of the followup, three patients (5.76%) between 1 and 2 years, and 10 patients (19.23%) between 2 and 7 years of the followup. Regional lymph node dissection was performed on fourteen patients and was associated with regional isolated limb perfusion with melphalan and tumor necrosis factor alpha in one case. Five patients had already distant metastases.

Thirty patients developed distant metastases: 43% of them at 5 years and 62% at 10 years. Of them, twenty-seven patients died because of disease and three are alive with disease (time of followup: 09, 63, 84 months). Distant metastases most frequently involved the lungs (27 patients), bones (2 patients), and distant lymph nodes (1 patient).

Twenty-four patients received some form of chemotherapy, and three patients had surgical treatment (accessible metastases sites and single localisation).

Various chemotherapeutic regimens for musculoskeletal sarcomas or for malignant melanoma, in adjuvant aim or in curative one, were employed, including actinomycin, Adriblastina, cyclophosphamide, carboplatine, cisplatine; dacarbazine, etoposide, fotemustine; iosfamide, interleukin 2, ifosfamide (3 g/m²) + dactinomycin (1,5 mg/m²) + vincristine (1,5 mg/m²); regional isolated limb perfusion with melphalan and tumor necrosis factor alpha, methotrexate, MAID: doxorubicine (15 mg/m²) + dacarbazine (250 mg/m²/j) + ifosfamide (2--2,85 g/m²/j), vincristine; VACA: cyclophosphamide (1,2 g/m²) + doxorubicine (30 mg/m²) + dactinomycin (0,5 mg/m²) + vincristine 1,5 mg/m²; intrferon and taxol.

In twenty-one patients, chemotherapy was discontinued, usually after three courses, because of tumor progression (18 patients) or major hematotoxicity (3 patients). Local radiotherapy for distant metastases sometimes briefly alleviated the pain and was mostly given to patients with skeletal metastases.

The overall survival rate was 59% at 5 years and 41% at 10 years ([Figure 1](#fig1){ref-type="fig"}). Median time of follow up was 120 months (11--348). On multivariate analysis, only tumor size (*P* : 0.01) emerged as a significant prognostic factor ([Table 2](#tab2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

These results confirmed the known clinical features of CCS originally reported by Enzinger \[[@B1]\]: arising primarily in young adults, predominance in distal extremities, and presenting as a slowly enlarging mass that has been evident for several months or even years. The principal sites of the neoplasm are the extremities, especially the region of the foot and ankle. The head, neck, and trunk regions are only rarely involved. In our study, forty-three tumors (82.69%) were located in the extremities. The most common tumor site was the foot (19 tumors). Fourteen tumors (26.92%) were considered proximal, and 38 tumors (73.07%) were considered distal. Our findings also revealed several important factors that predict the clinical behavior of CCS and disclosed problems awaiting solution.

Over half of all clear cell sarcoma reported in the literature measured less than 4 cm \[[@B2]\], a finding in accord with our series in which 57.69% of patients had lesions that measured less or equal to 4 cm. CCS mainly afflicts young adults between the ages of 20 to 40 years \[[@B4], [@B5]\], but in rare instances it may occur in the extremes of ages. In our study, the mean age was 33 and 26 years (range 6--81 years). Although some reports have found predominance in females \[[@B6]\], the gender distribution between males and females is equal \[[@B2]\]. CCS was slightly more common in male than female patients in our series.

CCS is characterized by a recurrent chromosomal translocation t(12; 22), which results in fusion of the EWS gene on 22q with the ATF1 gene on 12q \[[@B4]\]. This genomic abnormality may represent a good marker for identifying these tumors. In the current study, 90.32% of the analyzed tumors (28 of 31 tumors) had this translocation.

As previous studies \[[@B4]--[@B7]\], our data further suggests that CCS and conventional melanoma develop through different genetic pathways. Indeed, CCS is a sarcoma subtype, and the characteristic EWS/ATF1 translocation, resulting in the chimeric protein EWS/ATF1, is responsible for the melanocytic differentiation. EWS/ATF1 can bind the transcription factor MITF which in turn can lead to melanocytic differentiation with expression of the protein involved in melanin synthesis: tyrosinase, melanin, HMB45. Because of the extensive clinical, histologic, and immunohistochemical similarities with melanoma, we decided to analyze whether CCS also has mutations in the BRAF and NRAS gene. No mutation of the BRAF nor NRAS gene was identified in 95.54% of the analyzed tumors (21 of 22 tumors). The two tumours which were found to harbor mutations in the BRAF and NRAS gene also presented the ATF1-EWS fusion gene and were considered atypical. However, the absence of cutaneous involvement, histologic features (spindle and a few epithelioid cells arranged in a nested pattern), and immunohistochemistry (diffuse positivity for S100 protein and HMB45) strongly suggested a diagnosis of CCS.

Therefore, we support the hypothesis that CCS belongs to the soft tissue sarcoma family and that the melanin synthesis is due to the specific action of the chimeric EWF/ATF1 protein via MITF activation. Molecular genetic abnormalities have been reported in 3 small series of CCS involving 10 patients, 12 patients, and 9 patients \[[@B3]--[@B5]\]. To our knowledge, the current study represents the largest reported series of patients with CCS with emphasis on mutational statue on BRAF, NRAS gene, and cytogenetic study of translocation (12, 22) (q13, q12).

Size constituted the only criterion that was useful as a predictor of the biologic behaviour of CCS ([Table 3](#tab3){ref-type="table"}). In our series, on multivariate analysis, only tumor size (*P* : 0.01) emerged as a significant prognostic factor.

Tumor necrosis was also a significant indicator of poor prognosis, independent of tumor size \[[@B11], [@B12]\]. Indeed, we found that the presence of necrosis more than 50% associated with worse outcome. Of fourteen patients who had necrosis more than 50%, ten patients died, but on multivariate analysis, it was not a significant prognostic factor.

Unlike most soft tissue sarcomas, CCS often metastasizes to regional lymph nodes \[[@B1], [@B2]\]. Sixteen of our patients had lymph node metastases. A marked tendency for regional lymph node metastases has been observed by other authors, Chung and Enzinger reported a 53% rate, and Eckardt et al. \[[@B18]\] a 33% rate of lymph node metastases. Although we found lymph node metastases to be slightly less frequent than pulmonary metastases, they tended to occur earlier in the course of the disease. The role of regional lymph node dissection in CCS has not been established to date. Some authors recommend prophylactic elective lymph node dissection, whereas others suggest lymphadenectomy only in patients who show clinical lymphadenopathy \[[@B19]\]. Sentinel lymph node biopsy, which has been used successfully for the staging of patients with breast cancer and melanoma, may allow early detection of lymph node metastasis in patients with CCS \[[@B19], [@B20]\]. It is quite possible that, with diligent staging using sentinel node biopsy, some patients who are believed to have localized disease in the current series will turn out not to have localized disease, and this would have a significant impact on the analyses. Further investigations of the usefulness of sentinel lymph node biopsy in CCS are warranted.

Complete excision of the primary tumors appears to be the optimal approach to treatment, a conclusion that is shared by others \[[@B15]\]. Of the 29 patients who had local recurrences, 19 died of the tumors and 3 are alive with disease. These results suggest that local recurrence has a negative role in the management of CCS. In our series, successful treatment was best accomplished by excision with a wide surgical margin, with or without adjuvant radiation therapy. The presence of metastases, either at initial diagnosis or later in courses of the disease, was an ominous factor; no patients survived free of disease once metastatic CCS occurred.

The overall prognosis for CCS is poor \[[@B1]--[@B3]\]. In most cases, the disease pursues a relentlessly progressive course and terminates in death due to wide-spread dissemination. Although rapidly fatal progression may occur, late metastases are quite common after many years of freedom from disease. In our series, the 5-year survival was 59% at 5 years and 41% at 10 years. Similar findings have been reported in the literature ([Table 3](#tab3){ref-type="table"}), with local recurrence or metastases (or both) occurring as late as 29 years after the initial surgery \[[@B2], [@B15]\]. Thus, once a diagnosis of CCS is made, the patient is at risk for recurrent disease for many years and must be followed closely. Awareness of delayed progression is especially important considering the young age of the most patients.

The rarity of the disease makes it difficult to draw conclusive statements, but clear cell sarcoma shares many features with melanoma, including histological, immunophenotypic, ultrastructural, and similarities in gene expression patterns. However, clear cell sarcoma is genetically distinct lacking melanoma-associated BRAF mutations and instead harboring recurrent and characteristic chromosomal translocations involving the EWSR1 gene. Although the term malignant melanoma of soft parts persist, it is important that this lesion be loosely considered a MM, but rather segregated as a unique tumor of soft tissue.
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###### 

Clear cell sarcomas: clinical, histological, molecular, therapeutic, and follow-up data.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Age   Sex   Site             Size (cm)   Treatment\   CHT\                      Surgical\   LRec\    LNMet\   Met\     FU\      Status   EWS- ATF1   Mitoses   Necrose   Grade   BRAF15   NRAS 61
                                                  (\*)         regimens                  margin      (\*\*)   (\*\*)   (\*\*)   (\*\*)                                                             
  ------ ----- ----- ---------------- ----------- ------------ ------------------------- ----------- -------- -------- -------- -------- -------- ----------- --------- --------- ------- -------- ---------
  1      36    F     Buttock          6           Surg+R+CT    IVA                       pos         no       no       77       80       4        pos         10        0         2       neg      neg

  2      23    F     Shoulder         9           CT+Surg+R    Adri                      pos         no       no       9        12       4        pos         34        1         3       neg      neg

  3      11    M     Heel             4           CT+Surg+R    I                         neg         no       no       23       40       4        pos         12        1         3       neg      neg

  4      53    F     Foot             6           CT+Surg+R    IVA                       neg         14       no       7        16       1        pos         6         1         2       neg      neg

  5      57    F     Forearm          5           Surg+R                                 neg         23       no       no       45       0        pos         5         0         2       neg      neg

  6      23    M     Foot             2,5         Surg+R+CT    MAID; MTX, C              neg         no       no       no       11       0        pos         5         0         2       neg      neg

  7      34    F     Forearm          4           Surg+CT+R    Adri,I, Cispl, F, Ditic   pos         1        0        0        8        4        pos         18        1         3       ni       ni

  8      20    M     Hand             4           CT+surg+R    Adri, DTIC, limb perf     neg         no       no       no       28       0        pos         10        1         2       ni       ni

  9      46    F     Hand             1,2         Surg                                   neg         24       no       no       40       0        pos         5         1         2       ni       ni

  10     54    M     Foot             3           Surg+CT      MAID; MTX, C              pos         1        no       5        24       4        pos         18        2         3       ni       ni

  11     45    F     Foot             3           Surg+R                                 pos         no       no       no       12       ?        pos         8         1         2       ni       ni

  12     48    M     Foot             1,8         Surg+R                                 pos         no       no       no       60       0        pos         3         2         3       neg      neg

  13     37    M     Foot             2           Surg+R+CT    4 E+I, D                  pos         no       no       57       120      1        pos         2         0         2       ni       ni

  14     33    M     Leg              4           Surg+R+CT    6 I                       neg         no       87       87       96       4        pos         10        2         2       ni       ni

  15     31    M     Foot             ?           Surg+CT+R    INF+Adri+T/EI             neg         no       0        10       16       4        pos         20        2         3       ni       ni

  16     37    F     Foot             2           Surg+R+CT    Adri+I                    pos         no       no       no       87       0        pos         9         0         2       neg      neg

  17     42    F     Leg              6           Surg+CT+R    Adri+I                    pos         no       54       no       60       1        neg         15        1         2       neg      neg

  18     51    M     Thigh            15          Surg+R+CT    Adri+I+DTIC               pos         24       no       33       60       4        pos         12        2         3       ni       ni

  19     9     M     Sacrum           7           Surg+R+CT    IVA                       pos         12       no       12       20       4        ni          4         1         2       ni       ni

  20     31    M     Knee             10          Surg+CT+R    I+C+V+DITC                neg         no       18       no       20       4        pos         2         1         2       neg      neg

  21     45    M     Knee             4           Surg+CT+R    VACA                      neg         no       no       no       48       0        ni          3         2         2       ni       ni

  22     29    F     Foot             3           Surg+R                                 neg         12       no       16       40       4        pos         9         1         2       neg      neg

  23     26    M     Foot             3           Surg+CT+R    Adri+I                    neg         144      no       228      312      1        pos         5         1         2       neg      neg

  24     38    F     Thigh            6           Surg+CT+R    VACA                      pos         12       36       52       60       4        ni          9         1         2       ni       ni

  25     17    M     Behind bladder   4           Surg+CT      Adri+I                    neg         no       no       no       65       0        pos         10        1         2       ni       ni

  26     6     F     Arm              8           Surg+CT      V+Carbo+ epirubicin       pos         1        0        no       180      0        ni          9         1         3       ni       ni

  27     15    F     Scapula          5           Surg+CT      Carbo + Adria, IL2        pos         10       no       12       24       4        ni          2--4      1         2       ni       ni

  28     36    M     Tibia            3           Surg+CT      Adri+I                    pos         16       20       22       28       4        ni          10        1         2       ni       ni

  29     15    F     Scapula          5           Surg+CT      IVA, IL2, DTIC            neg         no       no       no       12       0        ni          4         1         2       ni       ni

  30     20    F     Scalp            4           Surg+CT+R    I+Adri                    pos         84       72       96       120      4        neg         2         1         2       neg      neg

  31     33    F     Hand             3           Surg+CT+R    Adri                      pos         48       30       36       52       4        ni          10        1         2       ni       ni

  32     32    M     Pelvis           9           Surg+CT+R    I+Adri                    neg         6        10       21       32       4        ni          10        1         2       ni       ni

  33     12    F     Foot             3           Surg+CT+R    IVA                       pos         no       no       no       144      0        ni          2         1         3       ni       ni

  34     14    M     Wrist            5 à 6       Surg+CT+R    IVA                       neg         no       no       no       120      0        ni          10        1         2       ni       ni

  35     29    M     Heel             2           Surg+CT+R    V+DITC+Adri +C            neg         24       no       76       82       4        ni          19        1         2       ni       ni

  36     28    M     Wrist            3 à 4       Surg+CT+R    IVA, IL2, DTIC            pos         no       no       24       39       4        ni          11        1         2       ni       ni

  37     10    M     Hip              5,5         Surg+CT+R    IVA                       pos         68       72       no       120      0        pos         18        1         2       neg      neg

  38     24    M     Foot             3           Surg+R                                 pos         no       no       no       156      0        ni          3         1         2       neg      neg

  39     13    M     Leg              3           Surg+CT+R    VACA                      neg         30       30       no       348      0        ni          21        1         2       ni       ni

  40     47    F     Foot             3           Surg+CT+R    VACA                      neg         24       no       no       240      1        ni          12        1         2       ni       ni

  41     76    F     foot             4           Surg                                   pos         12       no       12       42       4        ni          2         1         3       ni       ni

  42     34    M     Wrist            1           Surg+CT+R    VACA                      neg         56       no       no       264      0        pos         10        1         2       neg      pos

  43     40    M     Leg              4           Surg+CT+R    VACA                      pos         60       no       84       96       4        neg         7         2         2       neg      neg

  44     12    F     Foot             14          Surg+R                                 neg         36       no       no       84       0        ni          5         2         2       ni       ni

  45     73    M     Scapula          10          Surg+CT+R    Adri+V+C+Plat             pos         48       36       24       96       4        ni          29        2         3       ni       ni

  46     20    M     Scapula          6           CT+Surg+R    Adri+V+ DTIC+C            pos         18       18       18       24       4        pos         8         1         2       neg      neg

  47     33    M     Foot             5           Surg+CT      F                         pos         16       4        4        31       4        pos         9         1         2       neg      neg

  48     81    F     Foot             3           Surg                                   pos         240      no       250      254      4        ni          9         2         2       ni       ni

  49     46    M     Foot             4           Surg+CT+R    I                         neg         60       72       250      260      4        pos         24        2         3       pos      neg

  50     47    M     Hand             6           Surg+CT+R    VACA                      neg         no       no       96       144      4        pos         15        2         2       neg      neg

  51     29    F     Foot             2           Surg                                   pos         no       60       no       60       1        ni          10        2         2       ni       ni

  52     30    M     knee             10          Surg+CT+R    C+V+ Adri+DTIC            pos         no       6        18       36       4        pos         5         2         2       neg      neg
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

((\*) Surg: surgery, R: radiotherapy, CT: chemotherapy. (\*\*) LRec: local recurrence (months), LNMet: locoregional lymph node metastasis (months), Met: distant metastasis (months), and FU: followup (months). Status: 0: alive with no disease, 1: alive with disease, and 4: died of disease. Mitoses: number of mitoses per ten high power fields. neg: negative, pos: positive, ni: not identified. Necrosis: 0: no necrosis, 1: less than 50% of necrosis, 2: more than 50% of necrosis). A: actinomycin D; Adri: Adriblastina, C: cyclophosphamide, Carbo: carboplatin, cisplt: cisplatin; DITIC: dacarbazine, EPI: eoposide, F: fotemustine; I: ifosfamide, IL2: Interleukin 2, IVA: ifosfamide (3 g/m²) + dactinomycin (1,5 mg/m²) + vincristine (1,5 mg/m²); Limb perf: regional isolated limb perfusion with melphalan and tumor necrosis factor alpha, MTX: methotrexate, MAID: doxorubicin (15 mg/m²) + dacarbazine (250 mg/m²/j) + ifosfamide (2--2,85 g/m²/j), V: vincristine; VACA: cyclophosphamide (1,2 g/m²) + doxorubicin (30 mg/m²) + dactinomycin (0,5 mg/m²) + vincristine 1,5 mg/m²; INF: intrferon; T: taxol.

###### 

Multivariate analysis of overall survival.

  ------------------------------------------------------------------
  Variable   Number   5-year survival univariate *P*   Event-free\
                                                       Survival
  ---------- -------- -------------------------------- -------------
  Sex                                                  

   Men       30       0,83                             0,70

   Women     22                                        

  Age                                                  

   ≤30 y     22       0,32                             0,38

   \>30 y    30                                        

  Size                                                 

   ≤4 cm     30       0,06                             0,01

   \>4 cm    21                                        

  Mitoses                                              

   \<10      27       0,61                             0,44

   ≥10       25                                        

  Necrosis                                             

   \<50%     38       0,66                             0,47

   ≥50%      14                                        

  Grade                                                

   2         40       0,19                             0,16

   3         12                                        
  ------------------------------------------------------------------

###### 

Clinicopathologic studies of clear cell sarcoma.

  ---------------------------------------------------------------------------------------------------
  Reference                      Year   No. of patients   Five-year survival   Prognostic\
                                                                               factors
  ------------------------------ ------ ----------------- -------------------- ----------------------
  Sara et al. \[[@B9]\]          1990   17                40                   Size

  El-Naggar et al. \[[@B10]\]    1991   11                NA                   DNA content

  Lucas et al. \[[@B11]\]        1992   35                67                   Size, necrosis

  Montgomery et al. \[[@B12]\]   1993   58                63                   Size\*, necrosis\*

  Deenik et al. \[[@B13]\]       1999   30                30                   Size,\
                                                                               radiotherapy

  Finley et al. \[[@B14]\]       2001   8                 55                   Size

  Ferrari et al. \[[@B15]\]      2002   28                66                   Size, site, IRS\
                                                                               group

  Takahira et al. \[[@B16]\]     2004   14                33                   Mitosis

  Kawai et al. \[[@B17]\]        2007   75                47                   Size,\* depth, sex,\
                                                                               TNM

  Current study                  2005   52                59                   stage, surgical\
                                                                               margin size\*
  ---------------------------------------------------------------------------------------------------

NA indicates not available; IRS group, Intergroup Rhabdomyosarcoma Study Group.

\*Multivariate analysis.

[^1]: Academic Editor: Dražen Jukić
